Passage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization. Passage Bio, Inc. announced positive results from ...
(RTTNews) - Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company, Tuesday reported positive topline data from its Phase 1 studies of PALI-2108, which is being developed for the ...
FDA cleared the Harmony-HHT Phase 1/2 study design, enabling Atavistik Bio to leverage existing clinical data with ATV-1601 ...
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through ...
Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen ...
Legend Biotech (LGND) added ~26% in the morning hours on Tuesday after announcing initial results from an early-stage trial for LB2501, its in vivo CAR-T cell therapy targeting B-cell non-Hodgkin ...
VRB-103, a once-weekly oral amylin analog, demonstrated high potency and strong selectivity in vitro for human amylin receptors VRB-103 expected to enter the clinic in H2 2026 as a monotherapy and in ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Johnson & Johnson said Monday it will ...
Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years First juvenile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results